USPTO granted Patent US12590291B2 to Nichia Corporation on March 31, 2026, covering a method of inducing expression of calcium channels and calcium pumps by irradiating cells with UV light in the 315-325nm wavelength range. The patent specifically claims dihydropyridine receptor (DHPR), voltage-gated calcium channel (VGCC), ryanodine receptor (RYR), and sarcoendoplasmic reticulum Ca2+-ATPase (SERCA). The patent includes 10 claims and names four inventors: Shinpei Kawarai, Atsushi Tsukamoto, Yasuo Fujikawa, and Tomohiro Tsurumoto.

Entities conducting research or commercial development involving UV-induced calcium channel expression in the 315-325nm range should conduct freedom-to-operate analyses to assess potential patent infringement risks. Companies developing related therapeutic or research applications should review licensing options with Nichia Corporation. This patent does not impose regulatory compliance obligations but creates IP considerations for product development strategies.